There are currently 443 clinical trials in Memphis, Tennessee looking for participants to engage in research studies. Trials are conducted at various facilities, including St. Jude Children's Research Hospital, Saint Jude Children's Research Hospital, Baptist Memorial Hospital and Cancer Center-Memphis and University of Tennessee Health Science Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Pharmacogenetic Determinants Of Treatment Response In Children
NCT00730678
Recruiting
To investigate whether genetic polymorphisms in genes encoding proteins involved in the metabolism or effects of drugs or environmental agents influence the disposition or effects of these xenobiotic substrates. To investigate the nature of heritability and the genetic basis of pharmacogenetic traits by studying family members of individuals with specific genotypes.
Gender:
ALL
Ages:
All
Trial Updated:
07/10/2024
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: All Malignancies, Children Being Treated for Catastrophic Illness
Register for Updates
Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase
NCT04195347
Recruiting
This is a phase I/II clinical trial assessing the tolerability and efficacy of CM4620 in children and young adults with acute pancreatitis caused by asparaginase. The tolerability of CM4620 when given to patients receiving frontline chemotherapy will be determined. The effectiveness in reducing the severity of pancreatitis will be estimated. Primary Objectives To assess the safety of CM4620 administration in children and young adults with asparaginase associated pancreatitis (AAP). To profile... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
07/09/2024
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Acute Pancreatitis
Register for Updates
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
NCT04486352
Recruiting
This is a Phase IB/II multi-cohort study designed to evaluate the efficacy and safety of targeted agents with or without cancer immune checkpoint therapy with atezolizumab in participant with recurrent and/or persistent endometrial cancer. The main protocol provides a platform for genomic screening with homogeneous basic eligibility criteria in order to direct study participants into biomarker-matched study cohorts consisting of testing targeted agents.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/02/2024
Locations: Baptist Memorial Hospital, Memphis, Tennessee
Conditions: Endometrial Cancer
Register for Updates
Effects of Constipation Treatment in Chronic Kidney Disease: A Pilot Feasibility Trial
NCT06123195
Recruiting
Constipation is one of the most prevalent gastrointestinal disorders in patients with chronic kidney disease (CKD) and has been associated with their adverse kidney and cardiovascular outcomes; however, little is known about the effects of constipation treatment on clinical outcomes nor on outcome-related biochemical and microbiological parameters in patients with CKD. The investigators aim to test the feasibility of delivering an intervention with constipation treatment and determine its effect... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/02/2024
Locations: Memphis VA Medical Center, Memphis, Tennessee
Conditions: Chronic Kidney Disease, Constipation
Register for Updates
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2024
Locations: Baptist Memorial Hospital and Cancer Center-Memphis, Memphis, Tennessee +2 locations
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Register for Updates
Cardiopulmonary Function and Cerebral Blood Flow in Hodgkin Lymphoma Survivors
NCT06421987
Recruiting
SURVIVORS Study participants are being asked to take part in this research study called HODNIRS because the participant is a survivor of Hodgkin Lymphoma (HL) treated with chest radiation and bleomycin at St. Jude Children's Research Hospital. The study is being done to help investigators understand the link between long term effects of chest radiation and bleomycin for HL and brain function in survivors. Primary Objective To evaluate dynamic changes in CBF and oxygenation during exercise with... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/28/2024
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Hodgkin Lymphoma, Adult
Register for Updates
A Phase 2a Study of IV BCV in Subjects With Adenovirus Infection
NCT04706923
Recruiting
The purpose of this study is to determine the safety and tolerability of intravenous (IV) brincidofovir (BCV; SyB V-1901) 0.2 mg/kg, 0.3 mg/kg or 0.4 mg/kg dosed twice weekly (BIW) or 0.4 mg/kg dosed once weekly (QW) for 4 weeks in subjects with AdV, and IV BCV in subjects with CMV
Gender:
ALL
Ages:
2 months and above
Trial Updated:
06/20/2024
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Adenovirus Infections, Cytomegalovirus Infection
Register for Updates
Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults
NCT04262206
Recruiting
PREVENTABLE is a multi-center, randomized, parallel group, placebo-controlled superiority study. Participants will be randomized 1:1 to atorvastatin 40 mg or placebo. This large study conducted in community-dwelling older adults without cardiovascular disease (CVD) or dementia will demonstrate the benefit of statins for reducing the primary composite of death, dementia, and persistent disability and secondary composites including mild cognitive impairment (MCI) and cardiovascular events.
Gender:
ALL
Ages:
75 years and above
Trial Updated:
06/14/2024
Locations: VA Medical Center Memphis, Memphis, Tennessee
Conditions: Cognitive Impairment, Mild, Dementia, Cardiovascular Diseases
Register for Updates
Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer
NCT05181826
Recruiting
To acquire blood samples from subjects for various purposes, including: i) determining the sensitivity and specificity of select DNA methylation markers for the detection of various types of cancer, ii) identifying benign conditions that may induce false positive or false negative results, and iii) defining the effects of potential interfering substances, such as chemotherapy drugs.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2024
Locations: Methodist LeBonheur Healthcare, Memphis, Tennessee
Conditions: Cancer, Liver Cirrhosis, Chronic Hepatitis, Hepatitis B, Hepatitis C, Diabetes, COPD
Register for Updates
A Pilot Study to Evidence Improved Cranial Flap Fixation With a Bioresorbable Bone Adhesive
NCT06095531
Recruiting
This clinical pilot study will evaluate the use of a bioresorbable bone adhesive to improve cranial flap fixation at two study time points (at the time of fixation and 6 months). The aim of this Pilot Study is to demonstrate the safety and efficacy of the use of Tetranite for Cranial Flap Fixation (TN-CFF) to allow clinical study of the TN-CFF device in a greater number of patients.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/03/2024
Locations: Semmes Murphey Clinic, Memphis, Tennessee
Conditions: Craniotomy
Register for Updates
Improving Scientific Rigor of Renal Clinical Endpoints for Sickle Cell Anemia
NCT04380610
Recruiting
The investigators will attempt to develop a more accurate equation to estimate eGFR in pediatric and adult sickle cell patients
Gender:
ALL
Ages:
Between 5 years and 50 years
Trial Updated:
05/28/2024
Locations: St Jude Childrens Research Hospital, Memphis, Tennessee +1 locations
Conditions: Sickle Cell Disease, Renal Disease, Glomerular Disease
Register for Updates
Long-term Follow-up (LTFU) of Patients Treated With Genome-edited Autologous Hematopoietic Stem and Progenitor Cells (HSPC)
NCT06155500
Recruiting
CADPT03A12001 is a prospective, multi-center study that is designed to follow all enrolled patients who have received treatment with OTQ923 for long-term safety and efficacy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2024
Locations: St Jude Childrens Rsrch Hospital, Memphis, Tennessee
Conditions: Sickle Cell Disease
Register for Updates